MedTrace Logo

Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer

NCT01738815 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2021-10-22

No results posted yet for this study

Summary

The goal of this study is to test whether the drug valproic acid can cause changes in bladder tumors that might inhibit their growth.

Conditions

Interventions

DRUG

Valproic Acid

500 mg orally, once daily for up to 30 days

Sponsors & Collaborators

  • State University of New York - Upstate Medical University

    lead OTHER

Principal Investigators

  • Oleg Shapiro, MD · State University of New York - Upstate Medical University

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2013-05-31
Completion
2014-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01738815 on ClinicalTrials.gov